H.C. Wainwright reiterates Faeth Therapeutics stock rating at buy
H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after Phase 2 trial results. The trial showed a 33% response rate and 7.4-month median progression-free survival. FTH shares have fallen 41% since the pre-announcement close, trading at $12.92.
How this was made
The 30-second read
Why it matters
The reiteration of a Buy rating and a $60 target reflects confidence in the trial data, likely prompting short‑term buying interest.
Market read
First‑report Phase 2 results provide a fresh catalyst for FTH, with potential spillover to similar biotech stocks.
What to watch
Potential regulatory delays and competition from other endometrial cancer therapies could temper upside.
Background
Faeth Therapeutics (FTH) is a clinical‑stage biotech focused on PI3K/AKT/mTOR inhibitors. The PIK-201 trial is a key milestone before advancing to Phase 3.
Ticker impact
H.C. Wainwright reiterated a Buy rating with a $60 price target after Faeth Therapeutics reported Phase 2 PIK-201 trial results showing 33% response rate.
likely upward pressure as investors price in the encouraging trial outcomes and higher target price.
The trial results exceed benchmarks and multiple analysts raised targets, indicating a material catalyst for the stock.
Market effects
The data may lift sentiment across the biotech sector, especially other PI3K/AKT/mTOR pathway developers.
Limited to U.S. biotech investors; no broader regional effect.
Modest global relevance, primarily affecting U.S. and international biotech funds.
Counterpoint
The trial size is small and long-term efficacy remains uncertain; the stock could face volatility if Phase 3 fails.
Key entities
- companyFaeth Therapeutics
Biotech company developing PIKTOR combination therapy.
- analystH.C. Wainwright
Equity research firm that reiterated a Buy rating on FTH.

